SCHEMBL7102174

SCHEMBL7102174

CC(C)(C)OC(=O)Nc1cc(C(C)(C)O[SiH2]C(C)(C)C)cc(Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.38
ATR Q13535 1/20 0.38
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
LCK P06239 3/20 0.34
PTGER1 P34995 2/20 0.34
CYP2C9 P11712 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2B P29275 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
STK17B O94768 1/20 0.33
STK17A Q9UEE5 1/20 0.33
MAPKAPK2 P49137 2/20 0.32
ACSS2 Q9NR19 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25250667 0.80 GPR35 (0.43) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL3407084 0.78
SCHEMBL16147173 0.77 ATR (0.45) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL31248850 0.77 ATR (0.45) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL19022371 0.75 CA12 (0.36) SCN9AACSS2CA1
SCHEMBL29955278 0.75 ATR (0.44) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL27259792 0.74 ATR (0.43) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL30895246 0.74 ATR (0.43) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL21551425 0.73 ATR (0.48) SCN9AATRGSK3BDYRK1ALCK
SCHEMBL30931841 0.73 ATR (0.48) SCN9AATRGSK3BDYRK1ALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100567-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100567-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 SCN9A 4740/4885ATR 708/4885GSK3B 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.